Rifaximin is a derivative of rifamycin which acts by inhibiting bacterial ribonucleic acid (RNA) synthesis. It is virtually unabsorbed after oral administration; thus it is used primarily to treat local conditions within the gastrointestinal tract. In vitro data indicate rifaximin possesses good activity against species of Staphylococcus, Streptococcus and Enterococcus but lesser activity against species of Enterobacteriaceae. Bacterial resistance during exposure to rifaximin has been reported but its clinical importance remains to be fully defined.
Results of comparative trials demonstrate that rifaximin is similar in efficacy to neomycin and lactulose in patients with hepatic encephalopathy and appears to be better tolerated. In 1 study, cyclical administration of rifaximin for 15 days per month was associated with progressive improvement over a 3-month period. In patients with infectious diarrhoea, rifaximin induces more rapid improvement in stool consistency and decreased frequency of faecal evacuations when compared with placebo, and is similar in efficacy to neomycin. Available data suggest rifaximin may be of some use in acute diverticulitis, but its use for the prevention of inflammatory complications or for control of common symptoms of diverticu-losis requires further study. Preoperative treatment with rifaximin as antibacterial prophylaxis in colorectal surgery shows some potential but should be further investigated.
Overall, rifaximin may be useful as an alternative therapy in hepatic encephalopathy but more data are needed to better define its clinical potential in infectious diarrhoea, diverticular disease and as antibacterial prophylaxis prior to colorectal surgery.
In common with other rifamycin antibacterial agents, rifaximin acts on the β subunit of the deoxyribonucleic acid (DNA)-dependent ribonucleic acid (RNA) polymerase enzyme of bacteria to inhibit bacterial RNA synthesis.
In vitro data indicate that the susceptibility of Gram-positive organisms to rifaximin is greater than that of Gram-negative organisms. Rifaximin possesses good inhibitory activity against species of Staphylococcus, Streptococcus and Enterococcus as well as Bacillus cereus, Moraxella catarrhalis and Haemophilus influenzae. Activity is lower against species of Enterobacteriaceae, Pseudomonas, Acinetobacter and Helicobacter, conflicting data exist for activity against Bacteroides spp. Because rifaximin undergoes essentially no systemic absorption, measurable plasma drug concentrations are very low; therefore, in vitro susceptibility data, expressed as minimum concentrations inhibitory to 50% (MIC50) or 90% (MIC90) of strains tested, may not accurately predict antibacterial activity in the gastrointestinal tract.
Administration of rifaximin 800 mg/day to 10 healthy volunteers for 5 days resulted in a marked reduction in the numbers of some enteric bacteria which subsequently normalised within 1 to 2 weeks.
Bacterial resistance rates of 30 to 90% have been reported after 5 days of rifaximin treatment. Within 1 to 2 weeks after treatment was halted, resistance rates had generally decreased to less than 20% in most strains tested. After 12 weeks, no resistant strains were detected.
Rifaximin is used for localised action in the gastrointestinal tract and pharmacokinetic studies have aimed to verify its lack of systemic absorption after oral administration.
Rifaximin could not be detected in the plasma of 9 of 18 healthy men 4 hours after administration of a single 400mg dose, while drug concentrations were less than 6 μg/L in the remainder. Less than 0.025% of the rifaximin dose was recovered in urine after 48 hours; faecal rifaximin concentrations were not determined.
Bile samples from patients undergoing cholecystectomy who had received rifaximin 1200 mg/day for 2 preoperative days contained little or no drug, demonstrating a lack of hepatic distribution for rifaximin. This further indicates that rifaximin is essentially unabsorbed following oral administration.
At present, there is no information to indicate whether rifaximin undergoes gastrointestinal metabolism or inactivation, and data regarding the faecal excretion of rifaximin in humans are lacking.
The virtual lack of systemic absorption after oral administration indicates a potential role for rifaximin in localised conditions, mediated by susceptible bacteria, within the gastrointestinal tract. Rifaximin has been evaluated in the symptomatic management of hepatic encephalopathy, infectious diarrhoea, diverticular disease and as prophylaxis against postoperative complications following colorectal surgery.
Reductions in blood ammonia levels were reported in all groups of patients with hepatic encephalopathy after treatment with rifaximin, lactulose, neomycin or paromomycin. Although in double-blind trials a consistent differential response pattern was not always evident, rifaximin also appeared as effective as lactulose or neomycin in improving other parameters, such as mental state, electroencephalogram (EEG) irregularities and mental function test scores. In 1 study, cyclical administration of rifaximin for 15 days per month for 3 months was associated with progressive improvement in mental status over this time period.
After 5 to 7 days of treatment, improvement in diarrhoea and associated symptoms was evident in patients with infectious diarrhoea receiving rifaximin, neomycin or placebo. Symptomatic relief and normalisation of bowel function improved at a similar rate in rifaximin compared with neomycin recipients but more rapidly than in placebo recipients. These results require confirmation in well-controlled trials before definitive conclusions can be reached regarding the role of rifaximin in the management of infectious diarrhoea, where antibiotic therapy is deemed necessary.
Data from a small number of trials indicate that rifaximin, with or without various other strategies, may be of some benefit in patients with acute diverticulitis on the basis of symptomatic relief combined with an endoscopically verified decrease in mucosal swelling, hyperaemia, haemorrhagic suffusions and diffuse granules of the mucosa. The use of rifaximin for protection against the development of inflammatory complications in patients with symptomatic, uncomplicated diverticular disease or for symptomatic relief alone requires confirmation compared with more conservative measures.
The advantages of mechanical bowel cleansing plus antibacterial prophylaxis in patients undergoing colorectal surgery are well recognised and accepted. Results from a few small trials which have evaluated 3-day preoperative treatment with rifaximin showed some potential in this indication but further investigation is needed in trials comparing rifaximin with widely used 1-day preoperative treatments.
On the basis of clinical trial data, patient tolerability to rifaximin was as good as, and sometimes better than, that seen with comparative agents. Data extracted from those clinical trials that provided tolerability information indicated that gastrointestinal complaints, such as nausea, abdominal pain, flatulence and vomiting, occurred most frequently, each in less than 1% of the approximately 950 patients who received rifaximin. Persistent vomiting in 1 child resulted in the only documented treatment withdrawal. Urticarial rashes have occured infrequently after rifaximin administration.
Dosage and Administration
The recommended rifaximin dosage for adults and children older than 12 years is 10 to 15 mg/kg/day, while in younger children a higher daily dose of 20 to 30 mg/kg/day is suggested. Treatment duration should not exceed 7 days in children. Rifaximin should not be administered to patients with evidence of serious intestinal ulcerative lesions or obstruction.
This is a preview of subscription content, log in to check access.
Buy single article
Instant access to the full article PDF.
Price includes VAT for USA
Marchi E, Montecchi L, Venturini AP, et al. 4-Deoxypyrido[1′,2′:1,2]imidazo[5,4-c]rifamycin SV derivatives. A new series of semisynthetic rifamycins with high antibacterial activity and low gastroenteric absorption. J Med Chem 1985; 28: 960–3
Mandell GL, Sande MA. Antimicrobial Agents. In: Gilman AG, Rall TW, Nies AS, et al., editors. The pharmacological basis of therapeutics. 8th ed. v. 2. Singapore: McGraw-Hill Inc., 1992: 1146–64
Fera G, Agostinacchio F, Nigro M, et al. Rifaximin in the treatment of hepatic encephalopathy. Eur J Clin Res 1993; 4: 57–66
Ripa S, Mignini F, Prenna M, et al. In vitro antibacterial activity of rifaximin against Clostridium difficile, Campylobactor jejunii and yersinia spp. Drugs Exp Clin Res 1987; 13: 483–8
Venturini AP, Marchi E. In vitro and in vivo evaluation of L/105, a new topical intestinal rifamycin. Chemioterapia 1986; 5: 257–62
Eftimiadi C, DeLeo C, Schito GC. Treatment of hepatic encephalopathy with L/105, a new non-absorbable rifamycin. Drugs Exp Clin Res 1984; 10: 691–6
Lamanna A, Orsi A. In vitro activity of rifaximin and rifampicin against some anaerobic bacteria. Chemioterapia 1984; III: 365–7
Hoover WW, Gerlach EH, Hoban DJ, et al. Antimicrobial activity and spectrum of rifaximin, a new topical rifamycin derivative. Diagn Microbiol Infect Dis 1993 Feb; 16: 111–8
National Committee for Clinical Laboratory Standards. Methods for dilution antimicrobial susceptibility tests for bacteria that grow aerobically-2nd edition; Approved Standard. NCCLS Document M7-A2. Villanova, PA.: NCCLS; 1990.
Alvisi V, D’Ambriosi A, Onofri W, et al. Treatment of secretory diarrhoeas. A double-blind trial of the effectiveness of rifaximin (L 105) and neomycin. Clin Trials J 1984; 21: 215–23
Stornello C, Salanitri G. Controlled trial on the effectiveness of the new antidiarrheal drug rifaximin. Med Praxis 1987; 8: 69–78
Luttichau U, Arcangeli P, Sinapi S. The use of rifaximin in the treatment of acute diarrhoeal enteritis: open study. Panminerva Med 1985; 27: 129–1332
Alvisi V, D’Ambrosi A, Loponte A, et al. Rifaximin, a rifamycin derivative for use in treatment of intestinal bacterial infections in seriously disabled patients. J Int Med Res 1987; 15: 49–56
Delia Marchina M, Renzi G, Palazzini E. Infectious diarrhea in the aged: controlled clinical trial of rifaximin. Chemioterapia 1988; 7: 336–40
Sanfilippo A, Raciti Longo G, Raciti Longo A. Clinical experience with rifaximin in pediatric diarrhoeal syndromes. Med Praxis 1984; 5: 375–83
Vinci M, Gatto A, Giglio A, et al. Double-blind clinical trial on infectious diarrhoea therapy: rifaximin versus placebo. Curr Ther Res 1984: 92-9
Testa R, Eftimiadi C, Sukkar GS, et al. A non-absorbable rifamycin for treatment of hepatic encephalopathy. Drugs Exp Clin Res 1985; 11: 387–92
De Leo C, Eftimiadi C, Schito GC. Rapid disappearance from the intestinal tract of bacteria resistant to rifaximin. Drugs Exp Clin Res 1986; 12: 979–81
Neu HC. The crisis in antibiotic resistance. Science 1992 August 21; 257: 1064–73
Descombe JJ, Dubourg D, Picard M, et al. Pharmacokinetic study of rifaximin after oral administration in healthy volunteers. Int J Clin Pharmacol Res 1994; 14: 51–6
Verardi S, Verardi V. Bile rifaximin concentration after oral administration in patients undergoing cholecystectomy. Farmaco 1990 Jan; 45: 131–5
Acocella G. Clinical pharmacokinetics of rifampicin. Clin Pharmacokinet 1978; 3: 108–27
deAngelis L. L-105. Drugs Future 1982; 7: 260–1
Venturini AP. Pharmacokinetics of L/105, a new rifamycin, in rats and dogs, after oral administration. Chemotherapy Basel 1983; 29: 1–3
Cellai L, Colosimo M, Marchi E, et al. Rifaximin (L/105), a new topical intestinal antibiotic: pharmacokinetic study after single oral administration of H-rifaximin to rats. Chemioterapia 1984 December; 3(6): 373–7
Morgan MY. The treatment of chronic hepatic encephalopathy. Hepatogastroenterology 1991; 38: 377–87
Podolsky DK, Isselbacher KJ. Cirrhosis of the liver. In: Wilson JD, Braunwald E, Isselbacher KJ, et al., editors. Harrison’s principles of internal medicine. 12th ed. v. 2. New York: McGraw-Hill, Inc., 1991: 1340–50
Crossley IR, Williams R. Progress in the treatment of chronic portasystemic encephalopathy. Gut 1984; 25: 85–98
Maier KP. Progress in the treatment of portal-systemic encephalopathy (PSE). J Hepatol 1987; 5: 355–61
Festi D, Mazzella G, Parini P, et al. Treatment of hepatic encephalopathy with non-absorbable antibiotics. Ital J Gastroenterol 1992; 24 Suppl. 2: 14–6
Bucci L, Palmieri GC. Double-blind, double-dummy comparison between treatment with rifaximin and lactulose in patients with medium to severe degree hepatic encephalopathy. Curr Med Res Opin 1993; 13(2): 109–18
Massa P, Vallerino E, Dodero M. Treatment of hepatic encephalopathy with rifaximin: double blind, double dummy study versus lactulose. Eur J Clin Res 1993; 4: 7–18
Di Piazza S, Filippazzo MG, Valenza LM, et al. Rifaximine versus neomycin in the treatment of portosystemic encephalopathy. Ital J Gastroenterol 1991 Sep–Oct; 23: 403–7
Pedretti G, Calzetti C, Missale G, et al. Rifaximin versus neomycin on hyperammoniemia in chronic portal systemic encephalopathy of cirrhotics. A double-blind, randomized trial. Ital J Gastroenterol 1991 May; 23: 175–8
Festi D, Mazzella G, Orsini M, et al. Rifaximin in the treatment of chronic hepatic encephalopathy: results of a multicenter study of efficacy and safety. Curr Ther Res 1993 Nov; 54: 598–609
Parini P, Cipolla A, Ronchi M, et al. Effect of rifaximin and paromomycin in the treatment of portal-systemic encephalopathy. Curr Ther Res 1992 Jul; 52: 34–9
DeMarco F, Amato PS, D’Arienzo A. Rifaximin in collateral treatment of portal-systemic encephalopathy: a preliminary report. Curr Ther Res 1984; 36: 668–73
Carpenter CCJ. Acute infectious diarrheal diseases and bacterial food poisoning. In: Wilson JD, Braunwald E, Isselbacher KJ, et al., editors. Harrison’s principles of internal medicine. 12th ed. v. 1. New York: McGraw-Hill Inc., 1991: 519–24
Larson TA. Gastrointestinal infections and enterotoxigenic poisonings. In: DiPiro JT, Talbert RL, Hayes PE, et al., editors. Pharmacotherapy: a pathophysiologic approach. New York: Elsevier Science Publishing Co., Inc., 1989: 1166–78
DuPont HL, Cooperstock M, Corrado ML, et al. Evaluation of new anti-infective drugs for the treatment of acute infectious diarrhea. Clin Infect Dis 1992; 15(Suppl. 1): S228–35
Mazzitelli M, Brega G, Dirani D, et al. Antidiarrhoeal effectiveness and tolerance in man of a local antibiotic: rifaximin. Comparative assessment using a control drug. Eur Rev Med Pharmacol Sci 1984; VI: 301–6
Palermo G, di Gregorio P, Coffa G. Effectiveness of the L 105 compound in the treatment of acute diarrhoeal diseases. A short-term controlled study. Med Praxis 1984; 5: 147–52
Florentino F, Simioli F, Conte M, et al. Open study on the antidiarrhoeal effectiveness of the L 105 compound. Chemiotera-pia 1984; 3: 132–5
Lombardo S, Santangelo G. Therapeutic effectiveness of L 105, given in three pediatric formulations, as an intestinal antibacterial agent. Farmaco 1984; 39: 170–5
Corazza GR, Ventrucci M, Strocchi A, et al. Treatment of small intestine bacterial overgrowth with rifaximin, a non-absorbable rifamycin. J Int Med Res 1988; 16: 312–6
LaMont JT, Isselbacher KJ. Diseases of the small and large intestine. In: Wilson JD, Braunwald E, Isselbacher KJ, et al., editors. Harrison’s principles of internal medicine. 12th ed. v. 2. New York: McGraw-Hill, 1991: 1281–9
Almy TP, Howell DA. Diverticular disease of the colon. N Engl J Med 1980 Feb 7; 302: 324–31
Papi C, Cammari E. Non-absorbable antibiotics in the treatment of diverticular disease of the colon. Ital J Gastroenterol 1992; 24 Suppl. 2: 19–22
Parks TG. Natural history of diverticular disease of the colon. Clinics in Gastroenterology 1975; 4: 53–69
Piper DW, deCarle DJ, Doe WF, et al. Gastrointestinal and hepatic diseases. In: Speight TM, editor. Avery’s Drug Treatment. 3rd ed. Hong Kong: ADIS Press, 1987: 732–811
Torsoli A, Inoue M, Manousos O, et al. Diverticular disease of the colon: data relevant to management. Gastroenterol Int 1991; 4: 3–20
Papi C, Ciaco A, Koch M, et al. Efficacy of rifaximin on symptoms of uncomplicated diverticular disease of the colon. A pilot multicentre open trial. Ital J Gastroenterol 1992 Oct; 24: 452–6
Iosca N, Ferrieri A. Therapy and prophylaxis of acute diverticulitis with rifaximin. Recenti Prog Med 1993 Jan; 84: 49–53
Lombardo L, Lapertosa G. Medical treatment of outpatient diverticulitis of the colon: an open clinical-endoscopic-histo-logical study with a non-aminoglycoside entero-antibiotic -rifaximin (in Italian). Recenti Prog Med 1991; 82: 300–4
Giaccari S, Tronci S, Falconieri M, et al. Long-term treatment with rifaximin and lactobacilli in post-diverticulitic stenoses of the colon. Eur Rev Med Pharmacol Sci 1993; 15: 29–34
Michael KA, DiPiro JT. Antimicrobial prophylaxis in surgery. In: DiPiro JT, Talbert RL, Hayes PE, et al., editors. Pharmacotherapy: a pathophysiologic approach. New York: Elsevier Science Publishing Co., Inc., 1989: 1277–87
Gorbach SL. Antimicrobial prophylaxis for appendectomy and colorectal surgery. Rev Infect Dis 1991; 13 Suppl. 10: S815–20
Guglielmo BJ. Surgical antibiotic prophylaxis. In: Koda-Kimble MA, Young LY, editors. Applied therapeutics: the clinical use of drugs. 5th ed. Vancouver: Applied Therapeutics, Inc., 1992: 35–1–35–11
British National Formulary Number 27. British Medical Association and the Royal Pharmaceutical Society of Great Britain, London, March 1994.
Gruttadauria G, la Barbera F, Cutaia G, et al. Prevention of infection in colonic surgery by rifaximin. A controlled, prospective, randomized trial. Eur Rev Med Pharmacol Sci 1987; 9: 101–5
Verardi S, Verardi V, Fusillo M. Rifaximin effectiveness evaluation in the preparation of large intestine to surgery. Eur Rev Med Pharmacol Sci 1986; 8: 268–70
Scalco GB, Rossi MR, Rubbini M, et al. Rifaximin: a new rifamycin for the prophylaxis of the septic complications in the large bowel surgery. Policlinico Sez. Chir. 1987; 94: 41–5
Berta V, Porta E, Di Gioia G. Antibiotic prophylaxis in colon surgery. 4th World Congress Poster Presentation, October 27-30, 1993.
Salcuni PF, Palazzini E. An evaluation of the therapeutic activity and tolerance of rifaximin, administered by stomach probe in patients after colorectal surgery. Aggiornamenti Med Chir 1988; 6: 1–7
Ambrosioni G, Giovannini G, Lambertini A, et al. Activity and tolerance evaluation in children of a new antidiarrhoeal drug: rifaximin. Clin Pediatr 1984; 66: 1–10
Alfa Wassermann S.p.A. Rifaximin prescribing information, Bologna, Italy.
Various sections of the manuscript reviewed by: L. Bucci, ‘Brera’ Medical Department, Niguarda Cà Granda Hospital, Milan, Italy; R.G. Finch, Department of Microbial Diseases, The City Hospital, Nottingham, England; G. Gasbarrini, Facoltà di Medicina e Chirurgia ‘Agostino Gemelli’, Università Cattolica del Sacro Cuore, Rome, Italy; G. Gentiloni Silveri, Facoltà di Medicina e Chirurgia ‘Agostino Gemelli’, Università Cattolica del Sacro Cuore, Rome, Italy; R.N. Jones, Department of Pathology, University of Iowa Hospitals and Clinics, Iowa City, Iowa, USA; S.D.R. Lang, Microbiology Laboratory, Middlemore Hospital, Auckland, New Zealand; M.J.S. Langman, Department of Internal Medicine, Edgbaston, Birmingham, England; C. Scarpignato, Cattedra di Farmacologia, Università degli Studi di Parma, Parma, Italy; E. Strauss, Clinic of Gastroenterology, Hospital Heliopolis, São Paulo, Brazil.
About this article
Cite this article
Gillis, J.C., Brogden, R.N. Rifaximin. Drugs 49, 467–484 (1995). https://doi.org/10.2165/00003495-199549030-00009
- Hepatic Encephalopathy
- Diverticular Disease
- Minimum Inhibitory Concentration